Now showing items 1-2 of 2

    • Joll II, Jeffery Ethan; 0000-0001-7941-6380 (2022-03-15)
      Department: Biomedical Engineering
      In 2017 the sclerostin targeting monoclonal antibody Romosozumab was approved as a treatment for post-menopausal osteoporosis (PMO) despite cardiovascular side effects discovered in clinical trials. Previous studies indicated ...
    • Agrawal, Vineet; (D'Alto, Michele; Naeije, Robert; Romeo, Emanuele; Xu, Meng; Assad, Tufik R.; Robbins, Ivan M.; Newman, John H.; Pugh, Meredith E.; Hemnes, Anna R.; Brittain, Evan L. (Journal of the American Heart Association, 2019-09-23)
      Background-Identification of occult diastolic dysfunction often requires invasive right heart catheterization with provocative maneuvers such as fluid challenge. Non-invasive predictors of occult diastolic dysfunction have ...